News & Updates

Statin overuse in acute cerebral ischaemia linked to thousands of AEs per year

More than one-fifth of patients with acute cerebral ischaemia (ACI) appear to be receiving statins unnecessarily, which has the potential to cause higher than 5,600 adverse events (AEs) each year, including diabetes, myopathy, and eye disease, according to the results of a meta-analysis.

Original New Drug Application Approvals by US FDA (16-31 July 2024)

New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Sitagliptin Diabetes Mellitus DM Type 2 DPP4-inhibitors

One jab of corifollitropin alfa equipotent to daily 300 IU of follitropin beta

In a combined analysis of 3 phase III randomized trials presented at ESHRE 2024, a single dose of 150 µg or 100 µg of corifollitropin alfa is found to provide an ovarian response equivalent to daily doses of 300 IU or 297 IU of follitropin beta, respectively, during a single IVF cycle

Ovarian hyperstimulation syndrome ups risk of pregnancy complications

Women with ovarian hyperstimulation syndrome (OHSS) are at higher risk of experiencing postpartum haemorrhage, large birthweight, neonatal respiratory distress syndrome, and intraventricular haemorrhage, suggests a study presented at ESHRE 2024.

Is it unsafe to use GLP-1 RAs in early pregnancy?

Exposure to GLP-1 receptor agonist (RA) treatment during early pregnancy does not appear to increase the risk of complications in pregnant women, as shown in a study presented at ESHRE 2024.